Dr. Mads Daugaard and his team at VPC have developed a pulsed laser therapy that shows potential as an initial method for targeting and destroying cancer cells. https://t.co/RVtSTKKwgx
Have a look at our latest publication describing the development and pre-clinical qualification of therapeutic antibodies targeting cancer-specific glycosaminoglycans (sugar molecules).
https://t.co/vU5KNzf7p8
@VCHResearch@VanProstateCtr@Var2Pharma@UBC
#VCHRI20Years – @VanProstateCtr investigator Dr. Mads Daugaard is up next with a presentation commemorating 10 years of research innovation & commercialization.
Our spinoff company, SnapCyte has two exciting job opportunities: Marketing Coordinator (https://t.co/ssTwc2deaT) and Lab Assistant (https://t.co/GFk8T4lKQb). If interested please click the links!
Are you getting different cell confluence data than other lab members? With the SnapCyte™ app you get unbiased data in minutes, using your phone and lab microscope. Sign up to be a Beta Tester and first to try it below 👇
#AI#lifescience#biology
https://t.co/Lsj7gz3T3i
A study led by @VanProstateCtr researchers @nader_alnakouzi & @madsdaug1 has uncovered a vital clue behind the recurrence of prostate cancer following anti-androgen hormone therapy: https://t.co/kAPmXWYx1p
Congrats to my PhD student Zakir Tahiry and the other recipients of the 2022 PCFBC grant. Zakir is characterizing the prostate cancer glycocalyx in search for new targeting opportunities.
Thanks to your incredible support, and contributions big and small, we are proud to announce that we have been able to grant a total of $535,000 towards prostate cancer research projects in Canada this year. Learn more about each project at https://t.co/5lHmqrLa70
Meet the 18 teams taking the stage at the 2022 Venture Showcase!
We are excited for you to meet the ventures solving problems across climate, human health and social impact with new and returning ventures joining us at Robson Square Nov 23!
https://t.co/YtQMIptxDN
#VS22
Today we signed the agreement with a Canadian investor!
“This investment will allow SnapCyte Solutions Inc. to introduce the SnapCyte™ app on the global market and initiate development of new product lines”, says Dr. Mads Daugaard, CEO. Read more below👇
https://t.co/EFORyXR6Qg
BREAKING NEWS:
The 2022 #NobelPrize in Physiology or Medicine has been awarded to Svante Pääbo “for his discoveries concerning the genomes of extinct hominins and human evolution.”
🤳 Introducing @SnapCyte: a new #AI-powered app used in the analysis of cancer cells and other diseases at a microscopic scale! 🔬
💬 “The app returns precision data results within five minutes,” says CEO Dr. Mads Daugaard (@madsdaug1).
https://t.co/fKBOlPJQSd
#NewsRelease – An AI-driven smartphone app developed by @VanProstateCtr researcher Dr. Mads Daugaard will make affordable cell analytics accessible to scientists around the world: https://t.co/YQ8G1X2PX6 @madsdaug1 @UBCmedicine @VCHhealthcare
An AI-driven smartphone app developed by @VanProstateCtr researcher Dr. Mads Daugaard will make affordable cell analytics accessible to scientists around the world: https://t.co/zmDiGc0k1v @madsdaug1
We are SnapCyte Solutions Inc. and we are here to democratize life science research!
We are excited to announce our incorporation and letting you know that we are in business.
#biotech#AI#lifescience#biology https://t.co/XopTiFmNUi